Mười câu hỏi và mười câu trả lời để làm rõ “hộp đen” của nhà tạo lập thị trường: Tại sao các nhà đầu tư mạo hiểm lại tham gia vào hoạt động tạo lập thị trường? Liệu chủ dự án có thực sự dễ bị đâm sau lưng không?

Noile-Immune Biotech

company

About

Noile-Immune Biotech is a national cancer research center specializing in the development of cancer immunotherapies.

  • 11 - 50

Details

Last Funding Type
Corporate Round
Last Funding Money Raised
¥1B
Industries
Biotechnology
Founded date
Apr 1, 2015
Number Of Employee
11 - 50
Operating Status
Active

Neurymune Biotech Co., Ltd. is a national cancer research center specializing in the development of cancer immunotherapies based on CAR-T cell therapy and a venture company from Yamaguchi University.
They aim to be a leading company responsible for the next generation in the field of cancer immunotherapy.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
3
¥3.44B
Noile-Immune Biotech has raised a total of ¥3.44B in funding over 2 rounds. Their latest funding was raised on Mar 22, 2021 from a Series C round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Mar 22, 2021 Series C ¥2.38B 2 BiGEN Detail
May 31, 2018 Series Unknown ¥60M 2 Detail
Sep 4, 2017 Corporate Round ¥1B 1 Takeda Detail

Investors

Number of Lead Investors
Number of Investors
2
4
Noile-Immune Biotech is funded by 4 investors. BiGEN and Takeda are the most recent investors.
Investor Name Lead Investor Funding Round
BiGEN Yes Series C
Takeda Yes Corporate Round
Healthcare Innovation Series C
SAIKYO Series Unknown